299 related articles for article (PubMed ID: 33958148)
1. Current Therapy and Emerging Intravesical Agents to Treat Non-Muscle Invasive Bladder Cancer.
Bree KK; Brooks NA; Kamat AM
Hematol Oncol Clin North Am; 2021 Jun; 35(3):513-529. PubMed ID: 33958148
[TBL] [Abstract][Full Text] [Related]
2. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
3. The current landscape of salvage therapies for patients with bacillus Calmette-Guérin unresponsive nonmuscle invasive bladder cancer.
Packiam VT; Richards J; Schmautz M; Heidenreich A; Boorjian SA
Curr Opin Urol; 2021 May; 31(3):178-187. PubMed ID: 33742981
[TBL] [Abstract][Full Text] [Related]
4. Intravesical and alternative bladder-preservation therapies in the management of non-muscle-invasive bladder cancer unresponsive to bacillus Calmette-Guérin.
Steinberg RL; Thomas LJ; Nepple KG
Urol Oncol; 2016 Jun; 34(6):279-89. PubMed ID: 26777259
[TBL] [Abstract][Full Text] [Related]
5. Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Hannouneh ZA; Hijazi A; Alsaleem AA; Hami S; Kheyrbek N; Tanous F; Khaddour K; Abbas A; Alshehabi Z
Cancer Med; 2023 Dec; 12(24):21944-21968. PubMed ID: 38037752
[TBL] [Abstract][Full Text] [Related]
6. Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial.
Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown G; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Sawutz D; Philipson R; Coll R; Narayan VM; Treasure FP; Yla-Herttuala S; Parker NR; Dinney CPN
Lancet Oncol; 2021 Jan; 22(1):107-117. PubMed ID: 33253641
[TBL] [Abstract][Full Text] [Related]
7. Novel treatments in BCG failure. Where do we stand today?
Fragkoulis C; Glykas I; Bamias A; Stathouros G; Papadopoulos G; Ntoumas K
Arch Esp Urol; 2021 Sep; 74(7):681-691. PubMed ID: 34472437
[TBL] [Abstract][Full Text] [Related]
8. Emerging treatment options for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
Kokorovic A; Ory J; Saad F
Curr Opin Support Palliat Care; 2022 Mar; 16(1):48-53. PubMed ID: 35086977
[TBL] [Abstract][Full Text] [Related]
9. [Bacillus Calmette-Guérin (BCG) and alternatives : Drug treatment of high-risk non-muscle invasive bladder cancer].
Leucht K; Foller S; Grimm MO
Urologe A; 2021 Nov; 60(11):1400-1408. PubMed ID: 34709440
[TBL] [Abstract][Full Text] [Related]
10. Sequential Intravesical Valrubicin and Docetaxel for the Salvage Treatment of Non-Muscle-Invasive Bladder Cancer.
McElree IM; Packiam VT; Steinberg RL; Mott SL; Gellhaus PT; Nepple KG; O'Donnell MA
J Urol; 2022 Nov; 208(5):969-977. PubMed ID: 35830552
[TBL] [Abstract][Full Text] [Related]
11. Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial.
Mitra AP; Narayan VM; Mokkapati S; Miest T; Boorjian SA; Alemozaffar M; Konety BR; Shore ND; Gomella LG; Kamat AM; Bivalacqua TJ; Montgomery JS; Lerner SP; Busby JE; Poch M; Crispen PL; Steinberg GD; Schuckman AK; Downs TM; Svatek RS; Mashni J; Lane BR; Guzzo TJ; Bratslavsky G; Karsh LI; Woods ME; Brown GA; Canter D; Luchey A; Lotan Y; Krupski T; Inman BA; Williams MB; Cookson MS; Keegan KA; Andriole GL; Sankin AI; Boyd A; O'Donnell MA; Philipson R; Ylä-Herttuala S; Sawutz D; Parker NR; McConkey DJ; Dinney CPN
Eur Urol; 2022 Mar; 81(3):223-228. PubMed ID: 34933753
[TBL] [Abstract][Full Text] [Related]
12. Bacillus Calmette-Guérin Salvage Therapy: Definitions and Context.
Konety BR; Narayan VM; Dinney CPN
Urol Clin North Am; 2020 Feb; 47(1):1-4. PubMed ID: 31757292
[TBL] [Abstract][Full Text] [Related]
13. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S; Sana S; El-Zawahry A; Peabody J; Pearce T; Adams N; Deebajah M; Crabtree J; Delfino K; McVary K; Robinson K; Rao K
World J Urol; 2021 Oct; 39(10):3807-3813. PubMed ID: 33966128
[TBL] [Abstract][Full Text] [Related]
15. The effect of restaging transurethral resection on recurrence and progression rates in patients with nonmuscle invasive bladder cancer treated with intravesical bacillus Calmette-Guérin.
Sfakianos JP; Kim PH; Hakimi AA; Herr HW
J Urol; 2014 Feb; 191(2):341-5. PubMed ID: 23973518
[TBL] [Abstract][Full Text] [Related]
16. Intravesical chemotherapy plus bacille Calmette-Guérin in non-muscle invasive bladder cancer: a systematic review with meta-analysis.
Houghton BB; Chalasani V; Hayne D; Grimison P; Brown CS; Patel MI; Davis ID; Stockler MR
BJU Int; 2013 May; 111(6):977-83. PubMed ID: 23253618
[TBL] [Abstract][Full Text] [Related]
17. Immune therapies in non-muscle invasive bladder cancer.
Ho PL; Williams SB; Kamat AM
Curr Treat Options Oncol; 2015 Feb; 16(2):5. PubMed ID: 25757877
[TBL] [Abstract][Full Text] [Related]
18. Intravesical combination therapies for non-muscle invasive bladder cancer: Recent advances and future directions.
Li Y; Youssef SF; Buanz AB
Eur J Pharmacol; 2022 Jul; 926():175024. PubMed ID: 35580708
[TBL] [Abstract][Full Text] [Related]
19. Salvage Therapy Using Bacillus Calmette-Guérin Derivatives or Single Agent Chemotherapy.
Haas CR; McKiernan JM
Urol Clin North Am; 2020 Feb; 47(1):47-54. PubMed ID: 31757299
[TBL] [Abstract][Full Text] [Related]
20. Interferon alfa in the treatment paradigm for non-muscle-invasive bladder cancer.
Lamm D; Brausi M; O'Donnell MA; Witjes JA
Urol Oncol; 2014 Jan; 32(1):35.e21-30. PubMed ID: 23628309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
